

XXIX Congresso



Associazione Italiana  
Radioterapia e Oncologia clinica

# AIRO 2019

L'innovazione in Radioterapia  
e in Oncologia Clinica: un ponte verso il futuro

**RIMINI 27-29 SETTEMBRE**

PALACONGRESSI

**ACTINIC VAGINITIS IN PATIENTS TREATED WITH VAGINAL HDR  
BRACHYTHERAPY IN POST-OPERATIVE ENDOMETRIAL CANCER FIGO  
STAGE I: ROLE OF HYALURONIC ACID AND AMINO ACID VAGINAL CREAM**



**Valeria Chiofalo**

A.O.U. Città della Salute e della Scienza di Torino



- **Vaginal brachytherapy (VBT)** alone as adjuvant treatment in FIGO Stage I endometrial cancer showed satisfactory results in terms of favourable toxicity profile compared to EBRT
- Vaginal atrophy, adhesions, shortening and stenosis are the most common VBT related toxicity (**actinic vaginitis**)
- Symptomatic inflammation (50-70% of pts) and dyspareunia, may be critical to maintain women's healthy sexual life

## Radiation induced epithelial damage






To evaluate the effectiveness of a HA+AA vaginal cream in prevention of acute and late actinic vaginal toxicities after adjuvant HDR-VBT

■ *Eligibility:*

- Age 18 – 80
- Endometrial carcinoma FIGO stage I given surgery
- Adjuvant HDR-VBT:  
 $^{192}\text{Ir}$  30 Gy/5 fr  
 Vaginal cylinder implant  
 Previous CT simulation  
 Prescription dose at 5 mm from cylinder surface  
 3 cm length including cuff and upper third of the vagina





- *Evaluation parameters at time 0, 3 months, 1 year after treatment*
  - Subjective parameters
  - CTCAE 4.03 scale for adverse events (AEs)
  - Objective assessment (inflammatory signs inspected by the physician)



Treatment Group (n = 60)


HA vaginal cream 2 x/die, 4 weeks  
Starting first day of VBT

Control Group (n = 60)


No treatment during/after VTB

- Retrospective-observational study
- Accrual period: 26 months (Jan 2014 – Mar 2016)
- Age 53-80 years
- No concomitant medication allowed over the period of treatment and observation

## POST TREATMENT VAGINAL INFLAMMATION



## POST TREATMENT VAGINAL PAIN




G0: 60% vs 80%  
G2: 10% vs 25%  
G2: 6% vs 14%  
G3: 0% vs 1%




## POST TREATMENT VAGINAL DRYNESS

■ G0 ■ G1 ■ G2 ■ G3



## POST TREATMENT VAGINAL STRUCTURE

■ G0 ■ G1 ■ G2 ■ G3



G0: 50% vs 78%  
G1: 26% vs 12%  
G2: 16% vs 6%  
G3: 6% vs 2%



- Application of HA vaginal cream during VBT was shown to have **clinical benefit** for FIGO stage I endometrial cancer patients who received adjuvant HDR-VBT following surgery
- It appears to **reduce the severity** of mucosal reactions
- Optimal resolution of actinic vaginitis symptoms
- Prophylactic measure and treatment to improve **sexual QoL** in patients undergoing VBT